MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-25-2026
Penumbra Net Debt 2011-2026 | PEN
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Penumbra
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -152 M | -290 M | -133 M | -35 M | -24.6 M | -20.8 M | 9.52 M | -67.8 M | -50.6 M | -13.2 M | -19.5 M | -3.29 M | 1.87 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 9.52 M | -290 M | -61.5 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical devices industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
EDAP TMS S.A.
EDAP
|
-22.8 M | $ 3.71 | -5.12 % | $ 138 M |  France |
 |
GenMark Diagnostics, Inc.
GNMK
|
38.7 M | - | - | $ 1.77 B |  USA |
 |
Axonics Modulation Technologies
AXNX
|
-230 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
-32.4 M | - | 1.37 % | $ 20.5 M | USA |
 |
Profound Medical Corp.
PROF
|
-7.36 M | $ 5.82 | 13.01 % | $ 180 M |  Canada |
 |
Acutus Medical
AFIB
|
14.2 M | - | -26.83 % | $ 2.62 M | USA |
 |
BioSig Technologies
BSGM
|
252 K | - | 37.08 % | $ 85.7 M | USA |
 |
Allied Healthcare Products
AHPI
|
-3.31 M | - | 3.58 % | $ 2.21 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
6.46 M | - | -5.86 % | $ 30.6 M | USA |
 |
Conformis
CFMS
|
-26.2 M | - | - | $ 16.4 M | USA |
 |
Delcath Systems
DCTH
|
-42.5 M | $ 9.2 | 2.45 % | $ 330 M | USA |
 |
Dynatronics Corporation
DYNT
|
1.8 M | - | 14.99 % | $ 929 K | USA |
 |
Cardiovascular Systems
CSII
|
-64.6 M | - | 0.15 % | $ 844 M | USA |
 |
Second Sight Medical Products
EYES
|
961 K | - | -0.97 % | $ 54.4 M | USA |
 |
Apollo Endosurgery
APEN
|
-22.5 M | - | - | $ 475 M | USA |
 |
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | USA |
 |
CryoLife, Inc.
CRY
|
230 M | - | -4.14 % | $ 702 M | USA |
 |
CONMED Corporation
CNMD
|
802 M | $ 37.08 | 1.42 % | $ 1.15 B | USA |
 |
Smith & Nephew plc
SNN
|
1.5 B | - | - | $ 23.8 B |  Britain |
 |
Soliton, Inc.
SOLY
|
-31.6 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.02 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-2.3 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Electromed
ELMD
|
-10.5 M | $ 24.66 | -0.16 % | $ 208 M | USA |
 |
Misonix, Inc.
MSON
|
5.72 M | - | - | $ 462 M | USA |
 |
Helius Medical Technologies
HSDT
|
-5.12 M | $ 2.16 | 7.46 % | $ 1.31 M | USA |
 |
Neovasc
NVCN
|
-4.95 M | - | - | $ 111 M | Canada |
 |
Integra LifeSciences Holdings Corporation
IART
|
529 M | $ 9.55 | 0.1 % | $ 735 M | USA |
 |
Intersect ENT, Inc.
XENT
|
50.8 M | - | - | $ 955 M | USA |
 |
Inogen
INGN
|
-86.3 M | $ 6.42 | 1.58 % | $ 171 M | USA |
 |
IRIDEX Corporation
IRIX
|
-4.29 M | $ 1.33 | -1.85 % | $ 21.5 M | USA |
 |
IRadimed Corporation
IRMD
|
-52.1 M | $ 101.78 | 0.8 % | $ 1.29 B | USA |
 |
Cytosorbents Corporation
CTSO
|
11.2 M | $ 0.67 | -3.52 % | $ 36.5 M | USA |
 |
Aethlon Medical
AEMD
|
-4.85 M | $ 2.32 | 7.41 % | $ 3.62 M | USA |
 |
BIOLASE
BIOL
|
6.1 M | - | -13.19 % | $ 166 K | USA |
 |
LivaNova PLC
LIVN
|
-282 M | $ 63.3 | 1.44 % | $ 3.45 B | Britain |
 |
InspireMD
NSPR
|
-5.65 M | $ 1.77 | -1.12 % | $ 114 M | Israel |
 |
LENSAR
LNSR
|
-13.6 M | $ 5.58 | 0.36 % | $ 64.3 M | USA |
 |
AdaptHealth Corp.
AHCO
|
1.64 B | $ 11.39 | -0.78 % | $ 1.54 B | USA |
 |
Medtronic PLC
MDT
|
23.6 B | $ 87.89 | 1.51 % | $ 113 B | USA |
 |
MiMedx Group
MDXG
|
-148 M | $ 4.1 | -0.73 % | $ 606 M | USA |
 |
Invacare Corporation
IVC
|
299 M | - | - | $ 24.7 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
83.3 M | $ 16.23 | 2.01 % | $ 381 M | USA |
 |
Myomo
MYO
|
-4.79 M | $ 0.7 | -0.1 % | $ 29.3 M | USA |
 |
NanoVibronix
NAOV
|
-636 K | - | - | $ 1.08 M | USA |
 |
Inspire Medical Systems
INSP
|
-433 M | $ 51.41 | -1.27 % | $ 1.51 B | USA |
 |
Orthofix Medical
OFIX
|
78.5 M | $ 11.93 | 1.79 % | $ 472 M |  Curacao |